(Q41880426)

13 October 2017

Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy (English)

1 reference

13 October 2017

1 reference

Chiao-Jung Kao

1

1 reference

13 October 2017

Gregory T Wurz

2

1 reference

13 October 2017

Andreas Schröder

3

1 reference

13 October 2017

Michael Wolf

4

1 reference

13 October 2017

Michael W Degregorio

5

1 reference

13 October 2017

language of work or name

1 reference

12 September 2013

1 reference

13 October 2017

1 reference

13 October 2017

2

1 reference

13 October 2017

10

1 reference

13 October 2017

e26285

1 reference

Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896473

Victories and deceptions in tumor immunology: Stimuvax(®)

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896473

L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896473

L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896473

Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896473

Heterogeneity of mucin gene expression in normal and neoplastic tissues.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896473

Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24498545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24498545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24498545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/ONCI.26285

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

24498545

1 reference